Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database
- 9 September 2021
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 54 (10) , 1290-1297
Abstract
Summary: Background: Bevacizumab is used in the treatment of advanced malignancies and has a “black box” warning for gastrointestinal perforations. Despite this known side effect, there are no large descriptive series of patients who experience bevacizumab‐induced gastrointestinal perforations.Aim: To review and describe post‐market cases of bevacizumab‐induced gastrointestinal perforation reported by healthcare professionals to the United States Food and Drug Association Adverse Event Reporting System (FAERS) database.Methods: In total, 74 025 cases of bevacizumab‐induced adverse drug reaction were reported to FAERS from January 1 2004 to July 6 2021. We identified 2874 cases of bevacizumab‐induced gastrointestinal perforation. A total of 1375 cases were determined to contain complete patient demographic data after the removal of duplicates and were reviewed. Subgroup analysis was completed on gastro‐oesophageal perforations given the lack of prior data.Results: The average patient age was 61.9 ± 11.4 years. A total of 698 cases included descriptive locations of perforations with most occurring in the large intestine (385 cases, 55.2% of specifically described cases). Colorectal cancer was the most common indication for bevacizumab (691 cases, 50.3%) followed by ovarian cancer (197 cases, 14.3%) and non‐small cell lung cancer (182 cases, 13.2%). Death was reported in 554 patients (40.3% of cases). Sixty‐two cases of gastro‐oesophageal perforation were identified.Conclusions: This is the largest collective descriptive study of bevacizumab‐induced gastrointestinal perforations, and sheds light on this often fatal complication. We additionally identified and described a rare subgroup of patients experiencing bevacizumab‐induced gastro‐oesophageal perforation not previously described.Keywords
This publication has 23 references indexed in Scilit:
- Ovarian Cancer Development and MetastasisThe American Journal of Pathology, 2010
- Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic CancerJournal of Clinical Oncology, 2009
- Quantitative signal detection using spontaneous ADR reportingPharmacoepidemiology and Drug Safety, 2009
- A Population-Based Study of Perforated Diverticular Disease Incidence and Associated MortalityGastroenterology, 2009
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJournal of Clinical Epidemiology, 2008
- Pneumoperitoneum in the Cancer PatientAnnals of Surgical Oncology, 2007
- Colonoscopy Perforation Rate Stratified By Age: A Community Based StudyGastrointestinal Endoscopy, 2007
- Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200Journal of Clinical Oncology, 2007
- Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunityImmunology, 2006
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004